Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Hematologic Neoplasms Clinical Trials

A listing of Hematologic Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (8) clinical trials

Extracorporal Photopheresis Pilot Study

ECP will be given to the patients [UVAR®XTS TM Therakos system, Johnson & Johnson] according to the following schedule: Starting at day 21 after transplant, if hematologic recovery allowed it: 2 ECP per week the first 2 weeks, and 1 ECP per week during 1 month. Total = 8 ECP ...

Phase

Chemotherapy Followed by Allogeneic Stem Cell Transplantation in Treating Children With Hematologic Cancer

OBJECTIVES: Primary - Determine the efficacy and safety of non-myeloablative chemotherapy in facilitating donor engraftment after allogeneic stem cell transplantation with G-CSF mobilized peripheral blood stem cells in patients with pediatric hematopoietic malignancies. (Cohort 1) (closed to accrual as of 09/29/2005) - Determine the efficacy and safety of non-myeloablative chemotherapy ...

Phase

Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies

The primary objective of this study is to characterize the safety, tolerability and maximum tolerated dose of BMS-986016 administered alone or in combination with Nivolumab to subjects with relapsed hematologic malignancies. Co-primary objective is to investigate the preliminary efficacy of BMS-986016 in combination with nivolumab in subjects with relapsed or ...

Phase

A Study to Evaluate Safety Pharmacokinetics Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies

This is an open-label study, which consists of Part A (Dose Optimization Cohorts) and Part B (Expansion Cohorts). Part A consists of two dose optimization cohorts (cohort A1 and cohort A2) will determine the RP2D for the combination based on safety, pharmacokinetic, and pharmacodynamic assessments in participants with relapsed/refractory CLL/SLL ...

Phase

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab for Treatment of Hematologic Malignancies

This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.

Phase

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

This study is a Phase 1 Non-randomized/Phase 2 Randomized, open-label, prospectively and historically controlled trial of the safety and efficacy of a single ProTmune ex vivo programmed mobilized peripheral blood (mPB) cells for hematopoietic cell transplantation (HCT) in adult subjects aged 18 to 70 years with hematologic malignancies. A maximum ...

Phase

Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation

ApoGraft product is a mobilized peripheral blood cell product of a matched Related donor, collected via apheresis, which is exposed to the apoptotic mediator Fas Ligand (CD95L) prior to transplantation (Ex Vivo). The study is designed to address the aspects of engraftment and Prevention of Acute Graft versus Host Disease ...

Phase

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

The Phase 1 study duration for an individual patient will include a screening period for inclusion of up to 2 weeks, treatment with Isatuximab QW (every week) or Q2W (every 2 weeks) unless discontinued earlier due to safety or disease progression. Patients will be followed for a minimum of 30 ...

Phase